Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Exposure to simian virus 40 (SV40) is not associated with cancer in humans

Two upcoming studies by scientists at the National Cancer Institute (NCI), provide further evidence that exposure to simian virus 40 (SV40) is not associated with cancer in humans.

23 Aug 2004

Genmab's HuMax-CD4 receives U.S. orphan drug designation

Genmab has announced that HuMax-CD4 for the treatment of Mycosis Fungoides (MF), which constitutes 75% of all Cutaneous T-cell Lymphomas (CTCL), has been designated an orphan drug by the US Food and Drug Administration (FDA). The US prevalence of MF is estimated at 16,000 to 20,000.

23 Aug 2004

Scientists have developed the first mouse model Werner’s syndrome

Scientists have developed the first mouse model of a rare disease in which people age rapidly and start developing cancers and other diseases associated with the elderly when they are only about 30 years old.

20 Aug 2004

Two more drugs added to Medicare demonstration program

The Centers for Medicare & Medicaid Services has announced it is adding two more drugs to the list of drugs covered under a Medicare demonstration program providing substantial savings to beneficiaries with serious diseases, including cancer, multiple sclerosis, and rheumatoid arthritis.

17 Aug 2004

Scientists lead fight against blood cancers

The Leukaemia Research Fund has awarded £140,000 to three teams working within the Nuffield Department of Clinical Laboratory Sciences to find and improve treatments for leukaemia and related blood cancers.

7 Aug 2004

Cell Therapeutics receives Fast Track Designation for Pixantrone, treatment for aggressive non-Hodgkin's lymphoma

Cell Therapeutics, Inc. has received fast track designation from the U.S. Food and Drug Administration (FDA) for pixantrone, a novel anthracenedione, being investigated for the potential treatment of relapsed, aggressive non-Hodgkin's lymphoma (NHL).

12 Jul 2004

Increasing evidence a virus may play a role in breast cancer

A new study finds increasing evidence a virus may play a role in breast cancer. The study finds nearly three-quarters of a small sample of Tunisian breast cancer patients showed evidence of a virus similar to one known to cause breast cancer in mice, twice the rate seen in women in the United States.

12 Jul 2004

Understanding the role of c-Jun in repairing damaged nerve cells could help treat spinal injuries and increase our understanding of cancer

Research into the action of a key cancer gene has serendipitously uncovered its vital role in nerve growth, Cancer Research UK scientists reveal in a paper published on Wednesday.

8 Jul 2004

Severe sepsis causes around one in ten cancer deaths each year in the USA

Severe sepsis, is a costly complication in hospitalized cancer patients causing around one in ten cancer deaths each year in the USA, according to an article published today in Critical Care.

5 Jul 2004

Omega-3's - fatty acids, can be produced in bioengineered plants

Long-chain omega-3 polyunsaturated fatty acids (n-3 LC-PUFAs) have benefits regarding cardiovascular and inflammatory function, certain types of cancer, and maternal and infant health, according to recent peer-reviewed studies.

2 Jul 2004

The medical use of marijuana

The medical use of marijuana enjoys wide public support. More than 70% of respondents to recent surveys agree that marijuana should be available medically. Sources: Pew Research Center for the People & the Press conducted by Princeton Survey Research Associates. Feb. 14-19, 2001 and The Gallup Poll. March 19-21, 1999.

30 Jun 2004

Successes in frozen ovarian tissue technology may offer hope to women being treated for cancer

Doctors in Denmark have succeeded in producing a two-cell embryo after ovarian tissue was removed, frozen, and then thawed and replaced two years later.

29 Jun 2004

50,000 people in the U.S. with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery

50,000 people or 10% of the 500,000 people in the U.S with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery for coverage of life saving drugs.

26 Jun 2004

Tommy G. Thompson has announced a new Medicare program that will save seniors and the disabled substantial money

HHS Secretary Tommy G. Thompson today announced a new Medicare demonstration program that will save seniors and persons with disabilities substantial money

24 Jun 2004

Results from study of Rituxan in rheumatoid arthritis show promise

Genentech, Inc., Biogen Idec and Roche have announced that the New England Journal of Medicine published the results of a Phase IIa study showing that two doses of Rituxan® (Rituximab), administered two weeks apart, improved symptoms in patients with moderate-to-severe rheumatoid arthritis (RA) for up to 48 weeks when combined with methotrexate (MTX), compared to MTX alone.

16 Jun 2004

New drugs ease treatment of multiple myeloma

Science is increasingly commuting the death sentence that is a diagnosis of multiple myeloma. A cancer of the plasma cells that primarily strikes the elderly, multiple myeloma has been deadly because patients have been unable to withstand the aggressive treatment necessary to combat it.

10 Jun 2004

Drug Tarceva improves survival chance for patients with advanced lung cancer

Roche OSI Pharmaceuticals and Genentech today announced that their investigational drug Tarceva(TM) (erlotinib) achieved a significant 42.5% improvement in median survival compared to placebo in patients with advanced non-small cell lung cancer (NSCLC).

5 Jun 2004